0.018681 0.000000 0.000000 0.000000 0.013843 0.000000 0.000000 0.000000 0.013862 0.00000 0.00000 0.00000 Beattie, J.F. Breault, G.A. Byth, K.F. Culshaw, J.D. Ellston, R.P.A. Green, S. Minshull, C.A. Norman, R.A. Pauptit, R.A. Thomas, A.P. Jewsbury, P.J. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 4 90.00 90.00 90.00 53.529 72.239 72.137 C2 H4 O 44.053 ACETYL GROUP non-polymer C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C23 H26 N6 O2 418.492 1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENOXY)PROPAN-2-OL non-polymer C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking H2 O 18.015 WATER non-polymer C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C7 H14 N2 O4 190.197 n LYSINE NZ-CARBOXYLIC ACID L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking UK Bioorg.Med.Chem.Lett. BMCLE8 1127 0960-894X 13 3021 10.1016/S0960-894X(03)00638-3 12941325 Imidazo[1,2-A]Pyridines: A Potent and Selective Class of Cyclin-Dependent Kinase Inhibitors Identified Through Structure-Based Hybridisation 2003 US J.Med.Chem. JMCMAR 0151 0022-2623 39 4540 10.1021/JM960402A 8917641 High-Resolution Crystal Structures of Human Cyclin-Dependent Kinase 2 with and without ATP: Bound Waters and Natural Ligand as a Guide for Inhibitor Design 1996 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 100.0 1 IMAGE PLATE 1998-07-15 MARRESEARCH SINGLE WAVELENGTH M x-ray 1 0.875 1.0 PX9.6 SRS 0.875 SYNCHROTRON SRS BEAMLINE PX9.6 34045.531 CELL DIVISION PROTEIN KINASE 2 2.7.1.37 1 man polymer 418.492 1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENOXY)PROPAN-2-OL 1 syn non-polymer 18.015 water 123 nat water P33 PROTEIN KINASE no yes (ACE)MENFQKVEKIGEGTYGVVYKARNKLTGEVVAL(KCX)KIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIH TENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARA FGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVT SMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL XMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLV FEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTY THEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPS FPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n HUMAN sample 9606 HOMO SAPIENS 7108 SPODOPTERA FRUGIPERDA SF9 BACULOVIRUS 1 2.24 40 7.00 PROTEIN AT 10MG/ML WELL BUFFER CONTAINING 17.5% PEG3350, 200MM HEPES, PH7.0, 100MM AMMONIUM ACETATE, pH 7.00 repository Initial release Version format compliance Version format compliance 1 0 2003-09-04 1 1 2011-05-08 1 2 2011-07-13 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE HUMAN CYCLIN-DEPENDENT KINASE 2 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE-REGULATORY PROTEIN CKSHS1 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5- SULPHONATE BOUND CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDANT KINASE 2 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX WITH PHOSPHO-CDK2 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN OXINDOLE INHIBITOR THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN COMPLEX WITH THE INHIBITOR H717 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR M. SMEGMATIS ARYLAMINE N-ACETYL TRANSFERASE HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM E2F CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107 HUMAN CYCLIN-DEPENDENT KINASE 2 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A P27(KIP1)/CYCLIN A/CDK2 COMPLEX THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4-[(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH PKF049-365 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2- ONE CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL)BENZENESULFONAMIDE CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- DIHYDRO-1H-INDOLE STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR CYCLIN A BINDING GROOVE INHIBITOR H-ALA- ALA-ABU-ARG-ER-LEU-ILE-(P-F-PHE)-NH2 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX SHEET THE SHEET STRUCTURE OF THIS MOLECULE IS BIFURCATED. IN ORDER TO REPRESENT THIS FEATURE IN THE SHEET RECORDS BELOW, TWO SHEETS ARE DEFINED. PDBE Y PDBE 2003-06-24 REL HDY 1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENOXY)PROPAN-2-OL HOH water FUNCTION: PROBABLY INVOLVED IN THE CONTROL OF THE CELL CYCLE. INTERACTS WITH CYCLINS A, D, OR E. ACTIVITY OF CDK2 IS MAXIMAL DURING S PHASE AND G2. HDY 1298 2 HDY HDY 1298 A HOH 2001 3 HOH HOH 2001 A HOH 2002 3 HOH HOH 2002 A HOH 2003 3 HOH HOH 2003 A HOH 2004 3 HOH HOH 2004 A HOH 2005 3 HOH HOH 2005 A HOH 2006 3 HOH HOH 2006 A HOH 2007 3 HOH HOH 2007 A HOH 2008 3 HOH HOH 2008 A HOH 2009 3 HOH HOH 2009 A HOH 2010 3 HOH HOH 2010 A HOH 2011 3 HOH HOH 2011 A HOH 2012 3 HOH HOH 2012 A HOH 2013 3 HOH HOH 2013 A HOH 2014 3 HOH HOH 2014 A HOH 2015 3 HOH HOH 2015 A HOH 2016 3 HOH HOH 2016 A HOH 2017 3 HOH HOH 2017 A HOH 2018 3 HOH HOH 2018 A HOH 2019 3 HOH HOH 2019 A HOH 2020 3 HOH HOH 2020 A HOH 2021 3 HOH HOH 2021 A HOH 2022 3 HOH HOH 2022 A HOH 2023 3 HOH HOH 2023 A HOH 2024 3 HOH HOH 2024 A HOH 2025 3 HOH HOH 2025 A HOH 2026 3 HOH HOH 2026 A HOH 2027 3 HOH HOH 2027 A HOH 2028 3 HOH HOH 2028 A HOH 2029 3 HOH HOH 2029 A HOH 2030 3 HOH HOH 2030 A HOH 2031 3 HOH HOH 2031 A HOH 2032 3 HOH HOH 2032 A HOH 2033 3 HOH HOH 2033 A HOH 2034 3 HOH HOH 2034 A HOH 2035 3 HOH HOH 2035 A HOH 2036 3 HOH HOH 2036 A HOH 2037 3 HOH HOH 2037 A HOH 2038 3 HOH HOH 2038 A HOH 2039 3 HOH HOH 2039 A HOH 2040 3 HOH HOH 2040 A HOH 2041 3 HOH HOH 2041 A HOH 2042 3 HOH HOH 2042 A HOH 2043 3 HOH HOH 2043 A HOH 2044 3 HOH HOH 2044 A HOH 2045 3 HOH HOH 2045 A HOH 2046 3 HOH HOH 2046 A HOH 2047 3 HOH HOH 2047 A HOH 2048 3 HOH HOH 2048 A HOH 2049 3 HOH HOH 2049 A HOH 2050 3 HOH HOH 2050 A HOH 2051 3 HOH HOH 2051 A HOH 2052 3 HOH HOH 2052 A HOH 2053 3 HOH HOH 2053 A HOH 2054 3 HOH HOH 2054 A HOH 2055 3 HOH HOH 2055 A HOH 2056 3 HOH HOH 2056 A HOH 2057 3 HOH HOH 2057 A HOH 2058 3 HOH HOH 2058 A HOH 2059 3 HOH HOH 2059 A HOH 2060 3 HOH HOH 2060 A HOH 2061 3 HOH HOH 2061 A HOH 2062 3 HOH HOH 2062 A HOH 2063 3 HOH HOH 2063 A HOH 2064 3 HOH HOH 2064 A HOH 2065 3 HOH HOH 2065 A HOH 2066 3 HOH HOH 2066 A HOH 2067 3 HOH HOH 2067 A HOH 2068 3 HOH HOH 2068 A HOH 2069 3 HOH HOH 2069 A HOH 2070 3 HOH HOH 2070 A HOH 2071 3 HOH HOH 2071 A HOH 2072 3 HOH HOH 2072 A HOH 2073 3 HOH HOH 2073 A HOH 2074 3 HOH HOH 2074 A HOH 2075 3 HOH HOH 2075 A HOH 2076 3 HOH HOH 2076 A HOH 2077 3 HOH HOH 2077 A HOH 2078 3 HOH HOH 2078 A HOH 2079 3 HOH HOH 2079 A HOH 2080 3 HOH HOH 2080 A HOH 2081 3 HOH HOH 2081 A HOH 2082 3 HOH HOH 2082 A HOH 2083 3 HOH HOH 2083 A HOH 2084 3 HOH HOH 2084 A HOH 2085 3 HOH HOH 2085 A HOH 2086 3 HOH HOH 2086 A HOH 2087 3 HOH HOH 2087 A HOH 2088 3 HOH HOH 2088 A HOH 2089 3 HOH HOH 2089 A HOH 2090 3 HOH HOH 2090 A HOH 2091 3 HOH HOH 2091 A HOH 2092 3 HOH HOH 2092 A HOH 2093 3 HOH HOH 2093 A HOH 2094 3 HOH HOH 2094 A HOH 2095 3 HOH HOH 2095 A HOH 2096 3 HOH HOH 2096 A HOH 2097 3 HOH HOH 2097 A HOH 2098 3 HOH HOH 2098 A HOH 2099 3 HOH HOH 2099 A HOH 2100 3 HOH HOH 2100 A HOH 2101 3 HOH HOH 2101 A HOH 2102 3 HOH HOH 2102 A HOH 2103 3 HOH HOH 2103 A HOH 2104 3 HOH HOH 2104 A HOH 2105 3 HOH HOH 2105 A HOH 2106 3 HOH HOH 2106 A HOH 2107 3 HOH HOH 2107 A HOH 2108 3 HOH HOH 2108 A HOH 2109 3 HOH HOH 2109 A HOH 2110 3 HOH HOH 2110 A HOH 2111 3 HOH HOH 2111 A HOH 2112 3 HOH HOH 2112 A HOH 2113 3 HOH HOH 2113 A HOH 2114 3 HOH HOH 2114 A HOH 2115 3 HOH HOH 2115 A HOH 2116 3 HOH HOH 2116 A HOH 2117 3 HOH HOH 2117 A HOH 2118 3 HOH HOH 2118 A HOH 2119 3 HOH HOH 2119 A HOH 2120 3 HOH HOH 2120 A HOH 2121 3 HOH HOH 2121 A HOH 2122 3 HOH HOH 2122 A HOH 2123 3 HOH HOH 2123 A n 1 0 A MET 1 n 2 MET 1 A GLU 2 n 3 GLU 2 A ASN 3 n 4 ASN 3 A PHE 4 n 5 PHE 4 A GLN 5 n 6 GLN 5 A LYS 6 n 7 LYS 6 A VAL 7 n 8 VAL 7 A GLU 8 n 9 GLU 8 A LYS 9 n 10 LYS 9 A ILE 10 n 11 ILE 10 A GLY 11 n 12 GLY 11 A GLU 12 n 13 GLU 12 A GLY 13 n 14 GLY 13 A THR 14 n 15 THR 14 A TYR 15 n 16 TYR 15 A GLY 16 n 17 GLY 16 A VAL 17 n 18 VAL 17 A VAL 18 n 19 VAL 18 A TYR 19 n 20 TYR 19 A LYS 20 n 21 LYS 20 A ALA 21 n 22 ALA 21 A ARG 22 n 23 ARG 22 A ASN 23 n 24 ASN 23 A LYS 24 n 25 LYS 24 A LEU 25 n 26 LEU 25 A THR 26 n 27 THR 26 A GLY 27 n 28 GLY 27 A GLU 28 n 29 GLU 28 A VAL 29 n 30 VAL 29 A VAL 30 n 31 VAL 30 A ALA 31 n 32 ALA 31 A LEU 32 n 33 LEU 32 A KCX 33 n 34 KCX 33 A LYS 34 n 35 LYS 34 A ILE 35 n 36 ILE 35 A ARG 36 n 37 ARG 36 A LEU 37 n 38 LEU 37 A n 39 38 A n 40 39 A n 41 40 A n 42 41 A n 43 42 A n 44 43 A n 45 44 A n 46 45 A n 47 46 A THR 47 n 48 THR 47 A ALA 48 n 49 ALA 48 A ILE 49 n 50 ILE 49 A ARG 50 n 51 ARG 50 A GLU 51 n 52 GLU 51 A ILE 52 n 53 ILE 52 A SER 53 n 54 SER 53 A LEU 54 n 55 LEU 54 A LEU 55 n 56 LEU 55 A LYS 56 n 57 LYS 56 A GLU 57 n 58 GLU 57 A LEU 58 n 59 LEU 58 A ASN 59 n 60 ASN 59 A HIS 60 n 61 HIS 60 A PRO 61 n 62 PRO 61 A ASN 62 n 63 ASN 62 A ILE 63 n 64 ILE 63 A VAL 64 n 65 VAL 64 A LYS 65 n 66 LYS 65 A LEU 66 n 67 LEU 66 A LEU 67 n 68 LEU 67 A ASP 68 n 69 ASP 68 A VAL 69 n 70 VAL 69 A ILE 70 n 71 ILE 70 A HIS 71 n 72 HIS 71 A THR 72 n 73 THR 72 A GLU 73 n 74 GLU 73 A ASN 74 n 75 ASN 74 A LYS 75 n 76 LYS 75 A LEU 76 n 77 LEU 76 A TYR 77 n 78 TYR 77 A LEU 78 n 79 LEU 78 A VAL 79 n 80 VAL 79 A PHE 80 n 81 PHE 80 A GLU 81 n 82 GLU 81 A PHE 82 n 83 PHE 82 A LEU 83 n 84 LEU 83 A HIS 84 n 85 HIS 84 A GLN 85 n 86 GLN 85 A ASP 86 n 87 ASP 86 A LEU 87 n 88 LEU 87 A LYS 88 n 89 LYS 88 A LYS 89 n 90 LYS 89 A PHE 90 n 91 PHE 90 A MET 91 n 92 MET 91 A ASP 92 n 93 ASP 92 A ALA 93 n 94 ALA 93 A SER 94 n 95 SER 94 A ALA 95 n 96 ALA 95 A LEU 96 n 97 LEU 96 A THR 97 n 98 THR 97 A GLY 98 n 99 GLY 98 A ILE 99 n 100 ILE 99 A PRO 100 n 101 PRO 100 A LEU 101 n 102 LEU 101 A PRO 102 n 103 PRO 102 A LEU 103 n 104 LEU 103 A ILE 104 n 105 ILE 104 A LYS 105 n 106 LYS 105 A SER 106 n 107 SER 106 A TYR 107 n 108 TYR 107 A LEU 108 n 109 LEU 108 A PHE 109 n 110 PHE 109 A GLN 110 n 111 GLN 110 A LEU 111 n 112 LEU 111 A LEU 112 n 113 LEU 112 A GLN 113 n 114 GLN 113 A GLY 114 n 115 GLY 114 A LEU 115 n 116 LEU 115 A ALA 116 n 117 ALA 116 A PHE 117 n 118 PHE 117 A CYS 118 n 119 CYS 118 A HIS 119 n 120 HIS 119 A SER 120 n 121 SER 120 A HIS 121 n 122 HIS 121 A ARG 122 n 123 ARG 122 A VAL 123 n 124 VAL 123 A LEU 124 n 125 LEU 124 A HIS 125 n 126 HIS 125 A ARG 126 n 127 ARG 126 A ASP 127 n 128 ASP 127 A LEU 128 n 129 LEU 128 A LYS 129 n 130 LYS 129 A PRO 130 n 131 PRO 130 A GLN 131 n 132 GLN 131 A ASN 132 n 133 ASN 132 A LEU 133 n 134 LEU 133 A LEU 134 n 135 LEU 134 A ILE 135 n 136 ILE 135 A ASN 136 n 137 ASN 136 A THR 137 n 138 THR 137 A GLU 138 n 139 GLU 138 A GLY 139 n 140 GLY 139 A ALA 140 n 141 ALA 140 A ILE 141 n 142 ILE 141 A LYS 142 n 143 LYS 142 A LEU 143 n 144 LEU 143 A ALA 144 n 145 ALA 144 A ASP 145 n 146 ASP 145 A PHE 146 n 147 PHE 146 A GLY 147 n 148 GLY 147 A LEU 148 n 149 LEU 148 A ALA 149 n 150 ALA 149 A ARG 150 n 151 ARG 150 A ALA 151 n 152 ALA 151 A PHE 152 n 153 PHE 152 A GLY 153 n 154 GLY 153 A VAL 154 n 155 VAL 154 A PRO 155 n 156 PRO 155 A VAL 156 n 157 VAL 156 A ARG 157 n 158 ARG 157 A THR 158 n 159 THR 158 A TYR 159 n 160 TYR 159 A THR 160 n 161 THR 160 A HIS 161 n 162 HIS 161 A GLU 162 n 163 GLU 162 A VAL 163 n 164 VAL 163 A VAL 164 n 165 VAL 164 A THR 165 n 166 THR 165 A LEU 166 n 167 LEU 166 A TRP 167 n 168 TRP 167 A TYR 168 n 169 TYR 168 A ARG 169 n 170 ARG 169 A ALA 170 n 171 ALA 170 A PRO 171 n 172 PRO 171 A GLU 172 n 173 GLU 172 A ILE 173 n 174 ILE 173 A LEU 174 n 175 LEU 174 A LEU 175 n 176 LEU 175 A GLY 176 n 177 GLY 176 A CYS 177 n 178 CYS 177 A LYS 178 n 179 LYS 178 A TYR 179 n 180 TYR 179 A TYR 180 n 181 TYR 180 A SER 181 n 182 SER 181 A THR 182 n 183 THR 182 A ALA 183 n 184 ALA 183 A VAL 184 n 185 VAL 184 A ASP 185 n 186 ASP 185 A ILE 186 n 187 ILE 186 A TRP 187 n 188 TRP 187 A SER 188 n 189 SER 188 A LEU 189 n 190 LEU 189 A GLY 190 n 191 GLY 190 A CYS 191 n 192 CYS 191 A ILE 192 n 193 ILE 192 A PHE 193 n 194 PHE 193 A ALA 194 n 195 ALA 194 A GLU 195 n 196 GLU 195 A MET 196 n 197 MET 196 A VAL 197 n 198 VAL 197 A THR 198 n 199 THR 198 A ARG 199 n 200 ARG 199 A ARG 200 n 201 ARG 200 A ALA 201 n 202 ALA 201 A LEU 202 n 203 LEU 202 A PHE 203 n 204 PHE 203 A PRO 204 n 205 PRO 204 A GLY 205 n 206 GLY 205 A ASP 206 n 207 ASP 206 A SER 207 n 208 SER 207 A GLU 208 n 209 GLU 208 A ILE 209 n 210 ILE 209 A ASP 210 n 211 ASP 210 A GLN 211 n 212 GLN 211 A LEU 212 n 213 LEU 212 A PHE 213 n 214 PHE 213 A ARG 214 n 215 ARG 214 A ILE 215 n 216 ILE 215 A PHE 216 n 217 PHE 216 A ARG 217 n 218 ARG 217 A THR 218 n 219 THR 218 A LEU 219 n 220 LEU 219 A GLY 220 n 221 GLY 220 A THR 221 n 222 THR 221 A PRO 222 n 223 PRO 222 A ASP 223 n 224 ASP 223 A GLU 224 n 225 GLU 224 A VAL 225 n 226 VAL 225 A VAL 226 n 227 VAL 226 A TRP 227 n 228 TRP 227 A PRO 228 n 229 PRO 228 A GLY 229 n 230 GLY 229 A VAL 230 n 231 VAL 230 A THR 231 n 232 THR 231 A SER 232 n 233 SER 232 A MET 233 n 234 MET 233 A PRO 234 n 235 PRO 234 A ASP 235 n 236 ASP 235 A TYR 236 n 237 TYR 236 A LYS 237 n 238 LYS 237 A PRO 238 n 239 PRO 238 A SER 239 n 240 SER 239 A PHE 240 n 241 PHE 240 A PRO 241 n 242 PRO 241 A LYS 242 n 243 LYS 242 A TRP 243 n 244 TRP 243 A ALA 244 n 245 ALA 244 A ARG 245 n 246 ARG 245 A GLN 246 n 247 GLN 246 A ASP 247 n 248 ASP 247 A PHE 248 n 249 PHE 248 A SER 249 n 250 SER 249 A LYS 250 n 251 LYS 250 A VAL 251 n 252 VAL 251 A VAL 252 n 253 VAL 252 A PRO 253 n 254 PRO 253 A PRO 254 n 255 PRO 254 A LEU 255 n 256 LEU 255 A ASP 256 n 257 ASP 256 A GLU 257 n 258 GLU 257 A ASP 258 n 259 ASP 258 A GLY 259 n 260 GLY 259 A ARG 260 n 261 ARG 260 A SER 261 n 262 SER 261 A LEU 262 n 263 LEU 262 A LEU 263 n 264 LEU 263 A SER 264 n 265 SER 264 A GLN 265 n 266 GLN 265 A MET 266 n 267 MET 266 A LEU 267 n 268 LEU 267 A HIS 268 n 269 HIS 268 A TYR 269 n 270 TYR 269 A ASP 270 n 271 ASP 270 A PRO 271 n 272 PRO 271 A ASN 272 n 273 ASN 272 A LYS 273 n 274 LYS 273 A ARG 274 n 275 ARG 274 A ILE 275 n 276 ILE 275 A SER 276 n 277 SER 276 A ALA 277 n 278 ALA 277 A LYS 278 n 279 LYS 278 A ALA 279 n 280 ALA 279 A ALA 280 n 281 ALA 280 A LEU 281 n 282 LEU 281 A ALA 282 n 283 ALA 282 A HIS 283 n 284 HIS 283 A PRO 284 n 285 PRO 284 A PHE 285 n 286 PHE 285 A PHE 286 n 287 PHE 286 A GLN 287 n 288 GLN 287 A ASP 288 n 289 ASP 288 A VAL 289 n 290 VAL 289 A THR 290 n 291 THR 290 A LYS 291 n 292 LYS 291 A PRO 292 n 293 PRO 292 A VAL 293 n 294 VAL 293 A PRO 294 n 295 PRO 294 A HIS 295 n 296 HIS 295 A LEU 296 n 297 LEU 296 A n 298 297 A n 299 298 A author_and_software_defined_assembly PQS 1 monomeric A KCX 33 LYSINE NZ-CARBOXYLIC ACID A KCX 34 LYS 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N ILE 10 A N ILE 11 A O VAL 18 A O VAL 19 A N ALA 21 A N ALA 22 A O VAL 30 A O VAL 31 A N ALA 31 A N ALA 32 A O PHE 80 A O PHE 81 A N LEU 76 A N LEU 77 A O ILE 35 A O ILE 36 A N ILE 10 A N ILE 11 A O VAL 18 A O VAL 19 A N ALA 21 A N ALA 22 A O VAL 30 A O VAL 31 A N ALA 31 A N ALA 32 A O PHE 80 A O PHE 81 A O VAL 79 A O VAL 80 A N LEU 67 A N LEU 68 A N GLN 85 A N GLN 86 A O ILE 135 A O ILE 136 A N LEU 134 A N LEU 135 A O LYS 142 A O LYS 143 1 A CG ARG 36 A CG ARG 37 1 Y 1 A CD ARG 36 A CD ARG 37 1 Y 1 A NE ARG 36 A NE ARG 37 1 Y 1 A CZ ARG 36 A CZ ARG 37 1 Y 1 A NH1 ARG 36 A NH1 ARG 37 1 Y 1 A NH2 ARG 36 A NH2 ARG 37 1 Y 1 A CG LEU 37 A CG LEU 38 1 Y 1 A CD1 LEU 37 A CD1 LEU 38 1 Y 1 A CD2 LEU 37 A CD2 LEU 38 1 Y 1 A CG LYS 88 A CG LYS 89 1 Y 1 A CD LYS 88 A CD LYS 89 1 Y 1 A CE LYS 88 A CE LYS 89 1 Y 1 A NZ LYS 88 A NZ LYS 89 1 Y 1 A CG LEU 96 A CG LEU 97 1 Y 1 A CD1 LEU 96 A CD1 LEU 97 1 Y 1 A CD2 LEU 96 A CD2 LEU 97 1 Y 1 A CG ARG 122 A CG ARG 123 1 Y 1 A CD ARG 122 A CD ARG 123 1 Y 1 A NE ARG 122 A NE ARG 123 1 Y 1 A CZ ARG 122 A CZ ARG 123 1 Y 1 A NH1 ARG 122 A NH1 ARG 123 1 Y 1 A NH2 ARG 122 A NH2 ARG 123 1 Y 1 A CG ARG 150 A CG ARG 151 1 Y 1 A CD ARG 150 A CD ARG 151 1 Y 1 A NE ARG 150 A NE ARG 151 1 Y 1 A CZ ARG 150 A CZ ARG 151 1 Y 1 A NH1 ARG 150 A NH1 ARG 151 1 Y 1 A NH2 ARG 150 A NH2 ARG 151 1 Y 1 A CG LYS 178 A CG LYS 179 1 Y 1 A CD LYS 178 A CD LYS 179 1 Y 1 A CE LYS 178 A CE LYS 179 1 Y 1 A NZ LYS 178 A NZ LYS 179 1 Y 1 A ACE 0 A ACE 1 1 Y 1 A ASP 38 A ASP 39 1 Y 1 A THR 39 A THR 40 1 Y 1 A GLU 40 A GLU 41 1 Y 1 A THR 41 A THR 42 1 Y 1 A GLU 42 A GLU 43 1 Y 1 A GLY 43 A GLY 44 1 Y 1 A VAL 44 A VAL 45 1 Y 1 A PRO 45 A PRO 46 1 Y 1 A SER 46 A SER 47 1 Y 1 A ARG 297 A ARG 298 1 Y 1 A LEU 298 A LEU 299 1 Y 1 A A O O HOH HOH 2042 2060 1.91 1 A A O O ARG HOH 126 2039 1.94 1 A A O O HOH HOH 2063 2079 1.96 1 A A O O THR HOH 137 2046 1.99 1 A A O O HOH HOH 2053 2068 2.15 1 A A O O HOH HOH 2028 2080 2.17 1 6.94 0.90 118.30 125.24 A A A CB CG OD2 ASP ASP ASP 223 223 223 N 1 A A SD CE MET MET 91 91 -0.401 0.056 1.774 1.373 N 1 A ARG 126 84.44 -12.99 1 A ASP 127 -140.76 47.80 16.540 0.83 0.00 0.00 -0.23 0.00 -0.60 TLS REFINEMENT CARRIED OUT 0.241 0.204 0.205 1.91 43.03 979 18120 5.1 87.38 3.881 0.114 RANDOM 1 THROUGHOUT MOLECULAR REPLACEMENT 0.223 0.180 1.91 43.03 123 2439 31 0 2285 1.910 43.030 1OIR 20394 0.06600 1 21.7000 2.200 84.8 0.13700 1.90 2.01 10.300 1 2.00 73.3 refinement REFMAC data reduction MOSFLM data scaling SCALA phasing AMoRE CELL DIVISION PROTEIN KINASE 2 (E.C.2.7.1.37) Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified through Structure-based hybridisation 1 N N 2 N N 3 N N A THR 47 A THR 48 HELX_P A LEU 55 A LEU 56 1 1 9 A LYS 56 A LYS 57 HELX_P A LEU 58 A LEU 59 5 2 3 A LEU 87 A LEU 88 HELX_P A SER 94 A SER 95 1 3 8 A PRO 100 A PRO 101 HELX_P A HIS 121 A HIS 122 1 4 22 A LYS 129 A LYS 130 HELX_P A GLN 131 A GLN 132 5 5 3 A GLY 147 A GLY 148 HELX_P A GLY 153 A GLY 154 1 6 7 A ALA 170 A ALA 171 HELX_P A LEU 175 A LEU 176 1 7 6 A THR 182 A THR 183 HELX_P A ARG 199 A ARG 200 1 8 18 A SER 207 A SER 208 HELX_P A GLY 220 A GLY 221 1 9 14 A GLY 229 A GLY 230 HELX_P A MET 233 A MET 234 5 10 5 A ASP 247 A ASP 248 HELX_P A VAL 252 A VAL 253 1 11 6 A ASP 256 A ASP 257 HELX_P A LEU 267 A LEU 268 1 12 12 A SER 276 A SER 277 HELX_P A ALA 282 A ALA 283 1 13 7 A HIS 283 A HIS 284 HELX_P A GLN 287 A GLN 288 5 14 5 covale 1.335 A LEU 32 A C LEU 33 1_555 A KCX 33 A N KCX 34 1_555 covale 1.320 A KCX 33 A C KCX 34 1_555 A LYS 34 A N LYS 35 1_555 KINASE KINASE, PROTEIN KINASE 1OIR PDB 1 1OIR CDK2_HUMAN UNP 1 P24941 0 0 1OIR 0 0 1OIR A 1 1 1 1 298 1OIR 1 298 P24941 A 2 2 299 5 5 3 anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel A PHE 4 A PHE 5 A GLU 12 A GLU 13 A VAL 17 A VAL 18 A ASN 23 A ASN 24 A VAL 29 A VAL 30 A LEU 32 A LEU 33 A LYS 75 A LYS 76 A GLU 81 A GLU 82 A ILE 35 A ILE 36 A ARG 36 A ARG 37 A PHE 4 A PHE 5 A GLU 12 A GLU 13 A VAL 17 A VAL 18 A ASN 23 A ASN 24 A VAL 29 A VAL 30 A LEU 32 A LEU 33 A LYS 75 A LYS 76 A GLU 81 A GLU 82 A LEU 66 A LEU 67 A THR 72 A THR 73 A GLN 85 A GLN 86 A ASP 86 A ASP 87 A LEU 133 A LEU 134 A ILE 135 A ILE 136 A ILE 141 A ILE 142 A LEU 143 A LEU 144 BINDING SITE FOR RESIDUE HDY A1298 Software 9 A ILE 10 A ILE 11 9 1_555 A VAL 18 A VAL 19 9 1_555 A ALA 31 A ALA 32 9 1_555 A GLU 81 A GLU 82 9 1_555 A LEU 83 A LEU 84 9 1_555 A HIS 84 A HIS 85 9 1_555 A LYS 89 A LYS 90 9 1_555 A LEU 134 A LEU 135 9 1_555 A HOH 2050 C HOH 9 1_555 19 P 21 21 21